0
2022
Global Non Small-cell Lung Cancer Market

Global Non Small-Cell Lung Cancer Market

by Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others), by Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy), by Distribution Channel (Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A00544
Oct 2022 | Pages: 262
Tables: 147
Charts: 60
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

Global Non Small Cell Lung Cancer Market Research, 2031

The global non small cell lung cancer market size was valued at $15.3 billion in 2021, and is projected to reach $36.9 billion by 2031, growing at a CAGR of 9.3% from 2022 to 2031.

Non-small cell lung cancer is a type of lung cancer, in which malignant tumor cells are formed in the lungs. It includes group of different diseases, which behave similarly such as squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Adenocarcinoma is a type of non-small cell lung cancer, which is more common in women than men and more in young people than old age group of people. It is found common in people who have a history of smoking and those who are exposed to polluted air more than those who smoke regularly. Squamous cell carcinoma is another common type of non-small cell lung cancer, which mostly occurs due to smoking tobacco. It mostly occurs in the central part of the lungs, which is near to the main airway. Large cell carcinoma can be harder to treat as it can be found in any part of the lung and tends to spread faster than the rest of the two.

The overall impact of COVID-19 pandemic remained negative for key players in the non-small lung cancer treatment market. The decline is due to decrease in number of patients diagnosed with non-small cell lung cancer in 2020 owing to lockdown restrictions along with disruption of supply chain during pandemic resulting in shortage of therapeutics.

Global Non Small-Cell Lung Cancer Market

Historical overview

The market was analyzed qualitatively and quantitatively from 2021-2031. The non-small cell lung cancer market grow at a CAGR of around 9.3% from 2021-2031. Most of the growth was derived from the Asia-Pacific region owing to the improving health awareness, rise in disposable incomes, as well as well-established presence of domestic companies in the region.   

Market dynamics

The non small cell lung cancer market growth is majorly driven by increase in rate of tobacco consumption more by young group of people, intense air pollution, and unhealthy lifestyle. Exposure to air containing traces of metals such as asbestos, arsenic, and others, are major reasons of adenocarcinoma. Thus, increase in number of people smoking and following unhealthy lifestyle are some of the major factors causing NSCLC. Also, among all lung cancer cases, majority of patients are suffering from non-small cell lung cancer. For instance, according to National Centre for Biotechnology Information (NCBI), 85% of cases are non-small cell lung cancer cases. In addition, increase in research and development activities by key players such as Roche and Eli Lilly propels the growth of the market. The rise in prevalence of lung cancer drive the market growth. The increase in prevalence of lung cancer, which led to rise in demand for non-small cell lung cancer treatment. Non-small cell lung cancer makes for 80–85% of all lung cancer cases globally, owing to exposure to air pollution, active smoking, drinking tainted water, and passive smoking. However, it is treatable with a variety of medicines, including immunotherapy, targeted therapy, and others. Furthermore, excessive consumption of tobacco which causes the cancer is the key factor that propels the market growth. Two main causes of non-small cell lung cancer are excessive tobacco use and active participation in passive smoking. For instance, according to the (World Health Organization) WHO, in 2020, 22.3% of the global population used tobacco, 36.7% of all men and 7.8% of the world’s women. Additionally, rise in prevalence of the non-small cell Lung cancer supports the market growth. For instance, non-small cell Lung cancer makes up around 25% of cancer deaths in the U.S. In 2021, 1,898,160 new cancer cases and 608,570 cancer deaths were projected to occur in the U.S. Long-term air pollution exposure promotes the development of non-small cell lung cancer.

Furthermore, rise in prevalence of lung cancer occur in people who smoke and consume tobacco further contributes toward market growth. Smoking, environmental toxins, radiation exposure, and dietary supplement use are a few risk factors associated with lung cancer. For instance, according to the World Health Organization (WHO), about 2.21 million new instances of lung cancer reported across the globe in 2020, making it the second most frequent type of cancer globally.

However, high-cost expenditure in the treatment of non-small cell lung cancer negatively impacts the growth of the market. In addition, high costs associated with non-small cell lung cancer treatment impedes the market growth. Furthermore, stringent government rules for product approval hinders the growth of the market.

The outbreak of COVID-19 has disrupted workflows in the healthcare sector around the globe. Nearly all industries were impacted by COVID-19. Coronavirus crises led to strictly follow the social distancing rules, and visit hospitals only for emergency need have resulted in a significant decline in demand for treatment services from hospitals. This was expected to negatively affect the demand for treatment services of non-small cell lung cancer. The outbreak of COVID-19 impacted the market, as hospital and healthcare services were significantly reduced due to social distancing measures taken by governments to stop COVID-19 spread. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. Moreover, there has also been a negative effect on various services, including orthopedic implants. For instance, according to the Commonwealth Fund, it was estimated that there was nearly 60% initial decrease in overall outpatient visits by May 2020 due to COVID-19. This was expected to negatively affect the demand for orthopedic sessions as they are usually conducted in outpatient departments. In addition, according to an article published in Europe PMC, the pandemic affected outpatient clinics, emergency and elective surgery, rehabilitation, resident training, personnel management, use of personal protective equipment, telemedicine, and all sub-specialties of orthopedics.

The overall impact of COVID-19 pandemic remained negative for key players in the non small cell lung cancer industry. The decline is due to decrease in number of patients diagnosed with non-small cell lung cancer in 2020 owing to lockdown restrictions along with disruption of supply chain during pandemic resulting in shortage of therapeutics. 

Segmental Overview

The non-small cell lung cancer market is segmented on basis of type, treatment type, distribution channel, and region. By type, it is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma and others. By treatment type, it is divided into chemotherapy, immunotherapy, and targeted therapy. By distribution channel, it is segmented into hospital, drug stores and retail pharmacy, and online pharmacy. Region-wise, the market is studies across North America, Europe, Asia-Pacific, and LAMEA.

By type:  the adenocarcinoma segment held a major non small cell lung cancer market share in 2021, due to presence of large patient population suffering with adenocarcinoma and availability of broad portfolio of therapeutics for this indication. The squamous cell carcinoma segment is expected to register higher CAGR during the forecast period. For instance, according to American Gastroenterological Association, there were an estimated 604,100 new cases of esophageal cancer in 2020.

Global Non Small-Cell Lung Cancer Market

By treatment: the targeted therapy segment dominated the market in 2021 and is expected to continue this trend during the forecast period owing to distinct clinical benefits offered by this therapy such as minimal side effects along with availability of number of targeted therapeutics. In addition, rise in number of people turning to targeted therapy as a form of treatment for cancer, and targeted therapy is successful in upto 80% of cases. On the other hand, immunotherapy segment is expected to witness significant market growth from 2022 to 2031.

Global Non Small-Cell Lung Cancer Market

By distribution channel- Hospital pharmacy segment held a dominant share in 2021, and is anticipated to continue this trend during the forecast period. The dominance is due to increase in number of hospitalizations of patients suffering with NSCLC and presence of skilled professionals within these settings.

Global Non Small-Cell Lung Cancer Market

By region: The non small cell lung cancer market size is analyzed across North America, Europe, Asia-Pacific, and LAMEA.  North America accounted for a major share of the Non-small cell lung cancer market in 2021, and is expected to maintain its dominance during the forecast period.

The North America market was dominant, in terms of non small cell lung cancer market share in 2021, owing to well-established healthcare infrastructure, higher awareness among people regarding early diagnosis of cancer, presence of favorable reimbursement policies and strong presence of key players in this region.

Presence of several major players in the region drive the growth of the market. In addition, surge in concern among people for maintaining а healthy lifestyle and increase in the demand for non-small cell lung cancer treatments in the region, which is expected to propel the growth of the market. Furthermore, presence of well-established healthcare infrastructure, and increase in adoption rate of various therapies for non-small cell lung cancer are expected to drive the market growth.

On the other hand, Asia-Pacific expected to witness considerable growth during non small cell lung cancer market forecast, due to presence of large patient population and rise in research and development activities in the pharmaceutical sector. Asia-Pacific expected to grow at the highest rate during the forecast period. The market growth in this region is attributable to presence of companies in the region as well as growth in the purchasing power of populated countries, such as China and India. Moreover, rise in adoption of therapies for cancer and adoption of high-tech processing to improve the training program drive the growth of the market. Asia-Pacific offers profitable opportunities for key players operating in the non-small cell lung cancer market, thereby registering the fastest growth rate during the forecast period, owing to the growing infrastructure of industries, rise in disposable incomes, as well as well-established presence of domestic companies in the region. In addition, rise in organizations for cancer awareness within the region provides great opportunity for new entrants in this region. Moreover, increase in number of initiatives and significant investments from governments for the overall development of healthcare system propels growth of the non-small cell lung cancer market in developing countries.

Global Non Small-Cell Lung Cancer Market

COMPETITION ANALYSIS

Competitive analysis and profiles of the major players in the non small cell lung cancer industry, such as AstraZeneca PLC, Bristol-Myers Squibb Company, Inc., Eli Lilly, F. Hoffmann-La Roche Ltd., Merck & Co., Novartis AG, Inc., Pfizer Inc., Johnson and Johnson, Sanofi S.A, and Teva Pharmaceuticals Industries LTD. The key players that provides the non-small lung cancer treatment products propels the market growth. The some other key market players in the non-small cell lung cancer treatment such as Celgene Corporation, Astellas Pharmaceuticals, and Boehringer Ingelheim Pharmaceuticals, Inc., and others that provides the non-small lung cancer treatment products.

Some example of product approval in the market

In May 2021, Roche announced the approval of Tecentriq by European Commission to enhance product portfolio. Tecentriq was used for first line treatment for adults with metastatic non-small cell lung cancer.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global non small cell lung cancer market analysis from 2021 to 2031 to identify the prevailing global non small cell lung cancer market opportunity.
  • Market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global non small cell lung cancer market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global non small cell lung cancer market trends, key players, market segments, application areas, and market growth strategies.

Global Non Small-Cell Lung Cancer Market Report Highlights

Aspects Details
Market Size By 2031 USD 36.9 billion
Growth Rate CAGR of 9.3%
Forecast period 2021 - 2031
Report Pages 262
By Type
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Others
  • Adenocarcinoma
By Treatment Type
  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
By Distribution Channel
  • Hospital Pharmacy
  • Drug Store and Retail Pharmacy
  • Online Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, UK, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (Japan, China, Australia, India, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly and Company, boehringer ingelheim, Pfizer Inc., Celgene Corporation, Sanofi, Astrazeneca, Merck & Co., Inc.
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Adenocarcinoma

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market share analysis by country

    • 4.3 Squamous Cell Carcinoma

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market share analysis by country

    • 4.4 Large Cell Carcinoma

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market share analysis by country

    • 4.5 Others

      • 4.5.1 Key market trends, growth factors and opportunities

      • 4.5.2 Market size and forecast, by region

      • 4.5.3 Market share analysis by country

  • CHAPTER 5: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Chemotherapy

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market share analysis by country

    • 5.3 Targeted Therapy

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market share analysis by country

    • 5.4 Immunotherapy

      • 5.4.1 Key market trends, growth factors and opportunities

      • 5.4.2 Market size and forecast, by region

      • 5.4.3 Market share analysis by country

  • CHAPTER 6: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Hospital Pharmacy

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market share analysis by country

    • 6.3 Drug Store and Retail Pharmacy

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market share analysis by country

    • 6.4 Online Pharmacy

      • 6.4.1 Key market trends, growth factors and opportunities

      • 6.4.2 Market size and forecast, by region

      • 6.4.3 Market share analysis by country

  • CHAPTER 7: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 North America

      • 7.2.1 Key trends and opportunities

      • 7.2.2 North America Market size and forecast, by Type

      • 7.2.3 North America Market size and forecast, by Treatment Type

      • 7.2.4 North America Market size and forecast, by Distribution Channel

      • 7.2.5 North America Market size and forecast, by country

        • 7.2.5.1 U.S.
          • 7.2.5.1.1 Key market trends, growth factors and opportunities
          • 7.2.5.1.2 Market size and forecast, by Type
          • 7.2.5.1.3 Market size and forecast, by Treatment Type
          • 7.2.5.1.4 Market size and forecast, by Distribution Channel
        • 7.2.5.2 Canada
          • 7.2.5.2.1 Key market trends, growth factors and opportunities
          • 7.2.5.2.2 Market size and forecast, by Type
          • 7.2.5.2.3 Market size and forecast, by Treatment Type
          • 7.2.5.2.4 Market size and forecast, by Distribution Channel
        • 7.2.5.3 Mexico
          • 7.2.5.3.1 Key market trends, growth factors and opportunities
          • 7.2.5.3.2 Market size and forecast, by Type
          • 7.2.5.3.3 Market size and forecast, by Treatment Type
          • 7.2.5.3.4 Market size and forecast, by Distribution Channel
    • 7.3 Europe

      • 7.3.1 Key trends and opportunities

      • 7.3.2 Europe Market size and forecast, by Type

      • 7.3.3 Europe Market size and forecast, by Treatment Type

      • 7.3.4 Europe Market size and forecast, by Distribution Channel

      • 7.3.5 Europe Market size and forecast, by country

        • 7.3.5.1 Germany
          • 7.3.5.1.1 Key market trends, growth factors and opportunities
          • 7.3.5.1.2 Market size and forecast, by Type
          • 7.3.5.1.3 Market size and forecast, by Treatment Type
          • 7.3.5.1.4 Market size and forecast, by Distribution Channel
        • 7.3.5.2 France
          • 7.3.5.2.1 Key market trends, growth factors and opportunities
          • 7.3.5.2.2 Market size and forecast, by Type
          • 7.3.5.2.3 Market size and forecast, by Treatment Type
          • 7.3.5.2.4 Market size and forecast, by Distribution Channel
        • 7.3.5.3 UK
          • 7.3.5.3.1 Key market trends, growth factors and opportunities
          • 7.3.5.3.2 Market size and forecast, by Type
          • 7.3.5.3.3 Market size and forecast, by Treatment Type
          • 7.3.5.3.4 Market size and forecast, by Distribution Channel
        • 7.3.5.4 Italy
          • 7.3.5.4.1 Key market trends, growth factors and opportunities
          • 7.3.5.4.2 Market size and forecast, by Type
          • 7.3.5.4.3 Market size and forecast, by Treatment Type
          • 7.3.5.4.4 Market size and forecast, by Distribution Channel
        • 7.3.5.5 Spain
          • 7.3.5.5.1 Key market trends, growth factors and opportunities
          • 7.3.5.5.2 Market size and forecast, by Type
          • 7.3.5.5.3 Market size and forecast, by Treatment Type
          • 7.3.5.5.4 Market size and forecast, by Distribution Channel
        • 7.3.5.6 Rest of Europe
          • 7.3.5.6.1 Key market trends, growth factors and opportunities
          • 7.3.5.6.2 Market size and forecast, by Type
          • 7.3.5.6.3 Market size and forecast, by Treatment Type
          • 7.3.5.6.4 Market size and forecast, by Distribution Channel
    • 7.4 Asia-Pacific

      • 7.4.1 Key trends and opportunities

      • 7.4.2 Asia-Pacific Market size and forecast, by Type

      • 7.4.3 Asia-Pacific Market size and forecast, by Treatment Type

      • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel

      • 7.4.5 Asia-Pacific Market size and forecast, by country

        • 7.4.5.1 Japan
          • 7.4.5.1.1 Key market trends, growth factors and opportunities
          • 7.4.5.1.2 Market size and forecast, by Type
          • 7.4.5.1.3 Market size and forecast, by Treatment Type
          • 7.4.5.1.4 Market size and forecast, by Distribution Channel
        • 7.4.5.2 China
          • 7.4.5.2.1 Key market trends, growth factors and opportunities
          • 7.4.5.2.2 Market size and forecast, by Type
          • 7.4.5.2.3 Market size and forecast, by Treatment Type
          • 7.4.5.2.4 Market size and forecast, by Distribution Channel
        • 7.4.5.3 Australia
          • 7.4.5.3.1 Key market trends, growth factors and opportunities
          • 7.4.5.3.2 Market size and forecast, by Type
          • 7.4.5.3.3 Market size and forecast, by Treatment Type
          • 7.4.5.3.4 Market size and forecast, by Distribution Channel
        • 7.4.5.4 India
          • 7.4.5.4.1 Key market trends, growth factors and opportunities
          • 7.4.5.4.2 Market size and forecast, by Type
          • 7.4.5.4.3 Market size and forecast, by Treatment Type
          • 7.4.5.4.4 Market size and forecast, by Distribution Channel
        • 7.4.5.5 South Korea
          • 7.4.5.5.1 Key market trends, growth factors and opportunities
          • 7.4.5.5.2 Market size and forecast, by Type
          • 7.4.5.5.3 Market size and forecast, by Treatment Type
          • 7.4.5.5.4 Market size and forecast, by Distribution Channel
        • 7.4.5.6 Rest of Asia-Pacific
          • 7.4.5.6.1 Key market trends, growth factors and opportunities
          • 7.4.5.6.2 Market size and forecast, by Type
          • 7.4.5.6.3 Market size and forecast, by Treatment Type
          • 7.4.5.6.4 Market size and forecast, by Distribution Channel
    • 7.5 LAMEA

      • 7.5.1 Key trends and opportunities

      • 7.5.2 LAMEA Market size and forecast, by Type

      • 7.5.3 LAMEA Market size and forecast, by Treatment Type

      • 7.5.4 LAMEA Market size and forecast, by Distribution Channel

      • 7.5.5 LAMEA Market size and forecast, by country

        • 7.5.5.1 Brazil
          • 7.5.5.1.1 Key market trends, growth factors and opportunities
          • 7.5.5.1.2 Market size and forecast, by Type
          • 7.5.5.1.3 Market size and forecast, by Treatment Type
          • 7.5.5.1.4 Market size and forecast, by Distribution Channel
        • 7.5.5.2 Saudi Arabia
          • 7.5.5.2.1 Key market trends, growth factors and opportunities
          • 7.5.5.2.2 Market size and forecast, by Type
          • 7.5.5.2.3 Market size and forecast, by Treatment Type
          • 7.5.5.2.4 Market size and forecast, by Distribution Channel
        • 7.5.5.3 South Africa
          • 7.5.5.3.1 Key market trends, growth factors and opportunities
          • 7.5.5.3.2 Market size and forecast, by Type
          • 7.5.5.3.3 Market size and forecast, by Treatment Type
          • 7.5.5.3.4 Market size and forecast, by Distribution Channel
        • 7.5.5.4 Rest of LAMEA
          • 7.5.5.4.1 Key market trends, growth factors and opportunities
          • 7.5.5.4.2 Market size and forecast, by Type
          • 7.5.5.4.3 Market size and forecast, by Treatment Type
          • 7.5.5.4.4 Market size and forecast, by Distribution Channel
  • CHAPTER 8: COMPANY LANDSCAPE

    • 8.1. Introduction

    • 8.2. Top winning strategies

    • 8.3. Product Mapping of Top 10 Player

    • 8.4. Competitive Dashboard

    • 8.5. Competitive Heatmap

    • 8.6. Key developments

  • CHAPTER 9: COMPANY PROFILES

    • 9.1 F. Hoffmann-La Roche Ltd

      • 9.1.1 Company overview

      • 9.1.2 Company snapshot

      • 9.1.3 Operating business segments

      • 9.1.4 Product portfolio

      • 9.1.5 Business performance

      • 9.1.6 Key strategic moves and developments

    • 9.2 Novartis AG

      • 9.2.1 Company overview

      • 9.2.2 Company snapshot

      • 9.2.3 Operating business segments

      • 9.2.4 Product portfolio

      • 9.2.5 Business performance

      • 9.2.6 Key strategic moves and developments

    • 9.3 Pfizer Inc.

      • 9.3.1 Company overview

      • 9.3.2 Company snapshot

      • 9.3.3 Operating business segments

      • 9.3.4 Product portfolio

      • 9.3.5 Business performance

      • 9.3.6 Key strategic moves and developments

    • 9.4 Astrazeneca

      • 9.4.1 Company overview

      • 9.4.2 Company snapshot

      • 9.4.3 Operating business segments

      • 9.4.4 Product portfolio

      • 9.4.5 Business performance

      • 9.4.6 Key strategic moves and developments

    • 9.5 Eli Lilly and Company

      • 9.5.1 Company overview

      • 9.5.2 Company snapshot

      • 9.5.3 Operating business segments

      • 9.5.4 Product portfolio

      • 9.5.5 Business performance

      • 9.5.6 Key strategic moves and developments

    • 9.6 Merck & Co., Inc.

      • 9.6.1 Company overview

      • 9.6.2 Company snapshot

      • 9.6.3 Operating business segments

      • 9.6.4 Product portfolio

      • 9.6.5 Business performance

      • 9.6.6 Key strategic moves and developments

    • 9.7 Bristol-Myers Squibb Company

      • 9.7.1 Company overview

      • 9.7.2 Company snapshot

      • 9.7.3 Operating business segments

      • 9.7.4 Product portfolio

      • 9.7.5 Business performance

      • 9.7.6 Key strategic moves and developments

    • 9.8 Celgene Corporation

      • 9.8.1 Company overview

      • 9.8.2 Company snapshot

      • 9.8.3 Operating business segments

      • 9.8.4 Product portfolio

      • 9.8.5 Business performance

      • 9.8.6 Key strategic moves and developments

    • 9.9 Sanofi

      • 9.9.1 Company overview

      • 9.9.2 Company snapshot

      • 9.9.3 Operating business segments

      • 9.9.4 Product portfolio

      • 9.9.5 Business performance

      • 9.9.6 Key strategic moves and developments

    • 9.10 boehringer ingelheim

      • 9.10.1 Company overview

      • 9.10.2 Company snapshot

      • 9.10.3 Operating business segments

      • 9.10.4 Product portfolio

      • 9.10.5 Business performance

      • 9.10.6 Key strategic moves and developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 2. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ADENOCARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 3. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ADENOCARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 4. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR SQUAMOUS CELL CARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 5. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 6. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR LARGE CELL CARCINOMA, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 7. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR LARGE CELL CARCINOMA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 8. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 9. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 10. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 11. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 12. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 13. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 14. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 15. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR IMMUNOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 16. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 17. GLOBAL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 18. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 19. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 20. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 21. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR DRUG STORE AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 22. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ONLINE PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 23. GLOBAL NON SMALL-CELL LUNG CANCER MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 24. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
    TABLE 25. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 26. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 27. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 28. NORTH AMERICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 29. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 30. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 31. U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 32. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 33. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 34. CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 35. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 36. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 37. MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 38. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 39. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 40. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 41. EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 42. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 43. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 44. GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 45. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 46. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 47. FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 48. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 49. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 50. UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 51. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 52. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 53. ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 54. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 55. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 56. SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 57. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 58. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 59. REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 60. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 61. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 62. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 63. ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 64. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 65. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 66. JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 67. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 68. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 69. CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 70. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 71. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 72. AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 73. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 74. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 75. INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 76. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 77. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 78. SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 79. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 80. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 81. REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 82. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 83. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 84. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 85. LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
    TABLE 86. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 87. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 88. BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 89. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 90. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 91. SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 92. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 93. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 94. SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 95. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 96. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE, 2021-2031 (REVENUE, $MILLION)
    TABLE 97. REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
    TABLE 98.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
    TABLE 99.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
    TABLE 100.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
    TABLE 101.F. HOFFMANN-LA ROCHE LTD: NET SALES
    TABLE 102.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
    TABLE 103.NOVARTIS AG: COMPANY SNAPSHOT
    TABLE 104.NOVARTIS AG: OPERATING SEGMENTS
    TABLE 105.NOVARTIS AG: PRODUCT PORTFOLIO
    TABLE 106.NOVARTIS AG: NET SALES
    TABLE 107.NOVARTIS AG: KEY STRATERGIES
    TABLE 108.PFIZER INC.: COMPANY SNAPSHOT
    TABLE 109.PFIZER INC.: OPERATING SEGMENTS
    TABLE 110.PFIZER INC.: PRODUCT PORTFOLIO
    TABLE 111.PFIZER INC.: NET SALES
    TABLE 112.PFIZER INC.: KEY STRATERGIES
    TABLE 113.ASTRAZENECA: COMPANY SNAPSHOT
    TABLE 114.ASTRAZENECA: OPERATING SEGMENTS
    TABLE 115.ASTRAZENECA: PRODUCT PORTFOLIO
    TABLE 116.ASTRAZENECA: NET SALES
    TABLE 117.ASTRAZENECA: KEY STRATERGIES
    TABLE 118.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
    TABLE 119.ELI LILLY AND COMPANY: OPERATING SEGMENTS
    TABLE 120.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
    TABLE 121.ELI LILLY AND COMPANY: NET SALES
    TABLE 122.ELI LILLY AND COMPANY: KEY STRATERGIES
    TABLE 123.MERCK & CO., INC.: COMPANY SNAPSHOT
    TABLE 124.MERCK & CO., INC.: OPERATING SEGMENTS
    TABLE 125.MERCK & CO., INC.: PRODUCT PORTFOLIO
    TABLE 126.MERCK & CO., INC.: NET SALES
    TABLE 127.MERCK & CO., INC.: KEY STRATERGIES
    TABLE 128.BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
    TABLE 129.BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
    TABLE 130.BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
    TABLE 131.BRISTOL-MYERS SQUIBB COMPANY: NET SALES
    TABLE 132.BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES
    TABLE 133.CELGENE CORPORATION: COMPANY SNAPSHOT
    TABLE 134.CELGENE CORPORATION: OPERATING SEGMENTS
    TABLE 135.CELGENE CORPORATION: PRODUCT PORTFOLIO
    TABLE 136.CELGENE CORPORATION: NET SALES
    TABLE 137.CELGENE CORPORATION: KEY STRATERGIES
    TABLE 138.SANOFI: COMPANY SNAPSHOT
    TABLE 139.SANOFI: OPERATING SEGMENTS
    TABLE 140.SANOFI: PRODUCT PORTFOLIO
    TABLE 141.SANOFI: NET SALES
    TABLE 142.SANOFI: KEY STRATERGIES
    TABLE 143.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
    TABLE 144.BOEHRINGER INGELHEIM: OPERATING SEGMENTS
    TABLE 145.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
    TABLE 146.BOEHRINGER INGELHEIM: NET SALES
    TABLE 147.BOEHRINGER INGELHEIM: KEY STRATERGIES
  • LIST OF FIGURES

  • FIGURE 1.GLOBAL NON SMALL-CELL LUNG CANCER MARKET SEGMENTATION
    FIGURE 2.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031
    FIGURE 3.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031
    FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    FIGURE 5.PORTER FIVE-1
    FIGURE 6.PORTER FIVE-2
    FIGURE 7.PORTER FIVE-3
    FIGURE 8.PORTER FIVE-4
    FIGURE 9.PORTER FIVE-5
    FIGURE 10.TOP PLAYER POSITIONING
    FIGURE 11.GLOBAL NON SMALL-CELL LUNG CANCER MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    FIGURE 12.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,BY TYPE,2021(%)
    FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ADENOCARCINOMA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 14.COMPARATIVE SHARE ANALYSIS OF SQUAMOUS CELL CARCINOMA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 15.COMPARATIVE SHARE ANALYSIS OF LARGE CELL CARCINOMA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 17.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,BY TREATMENT TYPE,2021(%)
    FIGURE 18.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 20.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 21.GLOBAL NON SMALL-CELL LUNG CANCER MARKET,BY DISTRIBUTION CHANNEL,2021(%)
    FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DRUG STORE AND RETAIL PHARMACY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031(%)
    FIGURE 25.GLOBAL NON SMALL-CELL LUNG CANCER MARKET BY REGION,2021
    FIGURE 26.U.S. GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 27.CANADA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 28.MEXICO GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 29.GERMANY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 30.FRANCE GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 31.UK GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 32.ITALY GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 33.SPAIN GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 34.REST OF EUROPE GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 35.JAPAN GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 36.CHINA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 37.AUSTRALIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 38.INDIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 39.SOUTH KOREA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 40.REST OF ASIA-PACIFIC GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 41.BRAZIL GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 42.SAUDI ARABIA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 43.SOUTH AFRICA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 44.REST OF LAMEA GLOBAL NON SMALL-CELL LUNG CANCER MARKET,2021-2031($MILLION)
    FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
    FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
    FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
    FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
    FIGURE 49.COMPETITIVE DASHBOARD
    FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    FIGURE 51.F. HOFFMANN-LA ROCHE LTD.: NET SALES ($MILLION)
    FIGURE 52.NOVARTIS AG.: NET SALES ($MILLION)
    FIGURE 53.PFIZER INC..: NET SALES ($MILLION)
    FIGURE 54.ASTRAZENECA.: NET SALES ($MILLION)
    FIGURE 55.ELI LILLY AND COMPANY.: NET SALES ($MILLION)
    FIGURE 56.MERCK & CO., INC..: NET SALES ($MILLION)
    FIGURE 57.BRISTOL-MYERS SQUIBB COMPANY.: NET SALES ($MILLION)
    FIGURE 58.CELGENE CORPORATION.: NET SALES ($MILLION)
    FIGURE 59.SANOFI.: NET SALES ($MILLION)
    FIGURE 60.BOEHRINGER INGELHEIM.: NET SALES ($MILLION)

 
 

This section provides various opinions of the top-level CXOs in the non-small cell lungs cancer treatment market. In accordance to several interviews conducted, the adoption of non-small cell lungs cancer treatment market is expected to witness a significant rise with increase in prevalence of non-small cell lung cancer diseases and rapid growth in geriatric population with lung problems. The non-small cell lungs cancer treatment market has piqued the interest of healthcare providers, owing to numerous benefits offered by various key players to treat disorders. As the market is saturated with steady growth rate in developed nations, the Asia-Pacific region is expected to offer high growth opportunities to the key players.

According to the perspectives of CXOs of leading companies in the market, rise in incidence of non-small cell lung cancer, surge in geriatric population across the globe, technological advancements, and improvement of healthcare infrastructure in emerging nations are some of the major factors that drive the market growth. However, high cost of NSCLC medications and treatments is a significant inhibitor of market expansion. Also, few drugs have a deleterious effect on the body and several side effects, including anemia, appetite loss, edema, and fertility problems, further hampering the adoption rate.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. Factors such as increase in prevalence of lung cancer around the globe, along with rise in investment for R&D by public and private players are the key growth factor for the market.

A. The forecast period for Non-small Cell Lung Cancer Treatmenrt market is 2022 to 2031

A. North America is the largest regional market for Global Non Small Cell Lung Cancer

A. The market value of Non-small Cell Lung Cancer Treatmenrt market in 2022 is $36,934.19 million.

A. Top companies such as F. Hoffmann-La Roche Ltd, Astrazeneca, and Merck & Co., Inc. held a high market position in 2021.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
Global Non Small-cell Lung Cancer Market

Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,570
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Single User
  • $5,730
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Enterprise
    License/PDF

  • $9,600
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Oct 2023 - Oct 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers